Ver proyecto
Barcelona, ES · 3 known investors
ADmit Therapeutics develops the MAP-AD® test, a blood biomarker-based diagnostic tool that predicts progression from mild cognitive impairment to Alzheimer's disease dementia for patients with neurodegenerative diseases. The company operates as a certified clinical laboratory serving healthcare providers and researchers in precision medicine.